← Leaderboards
Keith D. Lindor
Mayo Clinic Coll Of Medicine, Rochester
$6,621,341
Attributed
$6,621,341
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$6,121,342 · 2
FDA$499,999 · 1
By mechanism
R01$6,400,832 · 2
R21$220,509 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Gregory J. Gores$22,244,646
- Lewis R Roberts$8,981,499
- E R Dickson$1,710,269
Others in their field
Top investigators on “Primary Sclerosing Cholangitis”
- Konstantinos N Lazaridis · Mayo Clinic Rochester$10,811,365
- John C Magee · University Of Michigan At Ann Arbor$9,936,069
- Robert M Merion · University Of Michigan At Ann Arbor$6,556,556
- Saul Joseph Karpen · Baylor College Of Medicine$5,707,416
- Michael H Nathanson · Yale University$5,063,077
- Gianfranco D. Alpini · Texas A&M University Health Science Ctr$4,924,434
Research focus
Primary Sclerosing CholangitisClinical TrialsClinical DataResearch PersonnelMedicalCellsLiverBiochemistryLiver FailureQuality Of LifeAlkaline PhosphataseDoseAffectCessation Of LifeLiver DiseasesCirrhosisSerumBiochemicalDocumentationBile FluidChronicEsophagealEtiologyCholangitis
Grant awards (13)
Investigation of the activity of vidofludimus calcium, a novel, orally available, small molecule inhibitor of dihydroorotate dehydrogenase, as a treatment for primary sclerosing cholangitis (PSC)$15,882
R21 · FY2019 · DK · contact PI
A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults with Primary Sclerosing Cholangitis$499,999
R01 · FY2018 · FD · contact PI
Investigation of the activity of vidofludimus calcium, a novel, orally available, small molecule inhibitor of dihydroorotate dehydrogenase, as a treatment for primary sclerosing cholangitis (PSC)$204,627
R21 · FY2018 · DK · contact PI
Multicentered Randomized Trial of High-dose Urso in PSC$676,733
R01 · FY2010 · DK · contact PI
Multicentered Randomized Trial of High-dose Urso in PSC$334,663
R01 · FY2010 · DK · contact PI
Multicentered Randomized Trial of High-dose Urso in PSC$669,326
R01 · FY2009 · DK · contact PI
Multicentered Randomized Trial of High-dose Urso in PSC$654,182
R01 · FY2008 · DK · contact PI
Multicentered Randomized Trial of High-dose Urso in PSC$726,723
R01 · FY2007 · DK · contact PI
Multicentered Randomized Trail of High-dose Urso in PSC$548,790
R01 · FY2006 · DK · contact PI
Multicentered Randomized Trail of High-dose Urso in PSC$561,996
R01 · FY2004 · DK
Multicentered Randomized Trail of High-dose Urso in PSC$558,758
R01 · FY2003 · DK
Multicentered Randomized Trail of High-dose Urso in PSC$554,863
R01 · FY2002 · DK
Multicentered Randomized Trial of High-dose Urso in PSC$614,799
R01 · FY2001 · DK